Solstice Advanced Materials 3Q26 Earnings Call - SOLSTICE ADVANCED MATERIALS INC

Financial Performance:

• Q3 2026 net sales reached $1.05 billion, an 8% year-over-year increase, exceeding the top end of guidance.
• GAAP net income was $80 million compared to a $35 million loss in Q3 2025; diluted EPS was $0.50.
• Adjusted diluted EPS was $0.80, while adjusted EBITDA rose 13% to $265 million (up from $235 million).
• Adjusted EBITDA margin expanded 109 basis points year-over-year to 25.3%, driven by sales growth and operating leverage.
• Organic net sales growth was 8%, fueled by volume and pricing improvements across all segments.
• Operating cash flow for the first nine months was $693 million; free cash flow was $368 million despite higher capex.
• Balance sheet shows total debt of ~$2 billion, cash of $714 million, and net debt of ~$1.25 billion (net leverage 1.3x).
• Liquidity totaled $1.7 billion, including $1 billion available on the revolving credit facility.
• $100 million in share repurchases were completed in Q3; remaining $400 million of the $500 million authorization to be substantially completed by Q1 2027.

Guidance and Future Outlook:

• Full-year 2026 net sales raised to $4.195–$4.22 billion; adjusted EBITDA raised to $1.05–$1.06 billion; adjusted diluted EPS raised to $2.90–$2.95.
• Q4 2026 guidance: Net sales $1.01–$1.035 billion, adjusted EBITDA $246–$256 million, adjusted EPS $0.57–$0.62.
• Full-year capital expenditures (capex) remain unchanged at $420–$440 million.
• Nuclear backlog grew to $2.6 billion with contracts extending through 2039; including commitments from multiple small modular reactor customers.
• Data center-related revenue (excluding nuclear) expected to represent ~6% of 2026 revenue, growing >50% YoY.
• Management expects normalization in refrigerant markets (HFO/HFC mix) and healthcare packaging volumes in 2027 after 2026 destocking.
• R&D spending target is ~3% of sales (currently ~2.6%) to support next-generation molecules and electronics innovations.

Business Segments and Product Lines:

• Refrigerants & Applied Solutions (RAS): Sales $726M (+6%); Adjusted EBITDA $251M (+3%); Margin 34.5%. Refrigerant sales up 8% to $433M; Healthcare packaging sales up 24% to $61M; Nuclear sales up 4% to $66M (including $30M impact from product loan returns); Building solutions sales down 5% to $167M.
• Electronic & Specialty Materials (ESM): Sales $320M (+13%); Adjusted EBITDA $68M (+44%); Margin expanded 453 bps to 21.2%. Electronic material sales surged 31% to $135M; Safety/Defense +3%; Research/Performance Chemicals +4%.
• Nuclear: Metropolis facility de-bottlenecking expected to yield 1–2k additional tons annually; production exceeding 10,000 tons this year.
• Strategic Initiatives: Completed transition of all legacy Honeywell TSA assets ahead of schedule and under budget.
• Capacity Expansion: $200M+ investment to double Spokane sputtering target capacity; majority of volume increments expected in 2028.

Market and Competitive Landscape:

• Solstice positioned as a differentiated advanced materials company with exposure to secular trends: nuclear energy, AI infrastructure, data centers, and thermal management.
• Data center constraints are increasingly material-driven (thermal loads, advanced chips), favoring Solstice's proprietary IP and manufacturing scale.
• Nuclear demand strengthened by carbon-free baseload needs, government lending, and the 2028 end of Russian-enriched uranium import waivers.
• Electronic materials market shows robust demand for deposition and thermal solutions; customers requesting demand pull-forward.
• Refrigerant market faces headwinds in residential 454B and stationary HVAC, offset by strong automotive, data center, and commercial demand.
• Metropolis is the only established uranium conversion facility in the U.S., holding a unique position to meet U.S. government unobligated UF6 requirements.

Risks and Challenges:

• Refrigerant Volatility: Ongoing destocking and headwinds in 454B/HFCs affecting residential markets; normalization expected in 2027.
• Capacity Constraints: Tight supply at the Spokane facility for sputtering targets; mitigated by accelerated capex and supplier coordination.
• Nuclear Project Timing: Large-scale expansion contingent on securing 80% customer commitments, DOE alignment, and finalizing net project costs; decision remains disciplined.
• Market Choppiness: Residential HVAC softness and construction sector decline impacting specific end markets within RAS.
• Execution Risk: Dependence on successful de-bottlenecking and capacity ramp-up to meet aggressive customer demand growth rates.

Management Commentary and Tone:

• Tone is confident and proactive, emphasizing "disciplined execution" and the successful standalone strategy following the Element Solutions merger termination.
• Management expressed strong conviction in the company's "organic growth algorithm," highlighting high-return projects and customer partnerships.
• CEO highlighted the completion of the standalone transition one year post-spin, focusing on operational excellence and margin improvement.
• CFO and CEO emphasized a balanced capital allocation approach: reinvesting in organic growth (R&D, capacity) before returning excess cash to shareholders.
• Management reaffirmed the 25% adjusted EBITDA margin commitment and the trajectory to achieve it.

Analyst Questions and Answers:

• Nuclear De-bottlenecking: Low-capital projects at Metropolis will add 1–2k tons by end of 2027; does not deter long-term expansion ambitions which are awaiting 80% customer commitment.
• Electronics Growth: Demand for thermal interface materials and sputtering targets is robust with no signs of slowdown; Spokane expansion acceleration will yield increments in 2027, major capacity in 2028.
• Refrigerant Outlook: Modest growth expected in Q4 2026; 454B headwinds persist but normalization expected in 2027 similar to healthcare destocking recovery.
• M&A Strategy: No transformational M&A on horizon; focus remains on organic growth and potential small "tuck-in" acquisitions. The failed Element deal was rejected by shareholders despite strategic logic.
• R&D Spending: Targeting ~3% of sales; currently ~2.6%; investment slightly impacted RAS margins but crucial for next-gen molecule development.
• Nuclear Pricing/Contracts: ~90% of capacity sold via long-term contracts; spot market represents ~10%. No specific pricing comments given for government unobligated material, but Metropolis is positioned to serve.
• Healthcare Packaging: 24% growth driven by destocking reversal; mid-single-digit CAGR (approx. 6%) expected in the long term.

Other Key Points:

• Solstice completed its independence from Honeywell one year ago, achieving full operational autonomy.
• Cash position increased ~$250 million since the spinoff; total shareholder returns (dividends + buybacks) totaled ~$136 million in that period.
• The company is actively developing next-gen refrigerant molecules and immersion cooling solutions for data centers.
• Nuclear backlog duration extension to 2039 indicates long-term visibility in the sector.
• Management highlighted "durable secular trends" as the primary growth engine, specifically aligning materials innovation with AI/thermal management needs.